



Brussels, 18.12.2024  
C(2024) 8911 final

**COMMISSION IMPLEMENTING DECISION**

**of 18.12.2024**

**on the financing of the second special measure to enhance manufacturing capacities and  
access to vaccines, medicines and health technologies and systems in Africa for 2024**

# COMMISSION IMPLEMENTING DECISION

of 18.12.2024

**on the financing of the second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024**

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU, Euratom) 2024/2509 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 2018/1046, No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012<sup>1</sup> and in particular Article 110 thereof,

Having regard to Regulation (EU) 2021/947 of the European Parliament and of the Council of 9 June 2021 establishing the Neighbourhood, Development and International Cooperation Instrument – Global Europe, amending and repealing Decision No 466/2014/EU and repealing Regulation (EU) 2017/1601 and Council Regulation (EC, Euratom) No 480/2009<sup>2</sup>, and in particular Article 23 (1) and (4) thereof,

Whereas:

- (1) In order to ensure the implementation of the second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024, it is necessary to adopt an annual financing decision, which constitutes the annual work programme, for 2024. Article 110 of Regulation (EU, Euratom) 2024/2509 ('the Financial Regulation') establishes detailed rules on financing decisions.
- (2) The envisaged assistance is to comply with the conditions and procedures set out by the restrictive measures adopted pursuant to Article 215 TFEU<sup>3</sup>.
- (3) The objective pursued by the measures to be financed under the Regulation (EU) 2021/947 forms part of the EU commitment to mobilise EUR 400 million from the emerging challenges and priorities cushion laid down in Article 17 of the NDICI – Global Europe to support African partner countries, strengthening local manufacturing and their health systems. The previous special measure from year 2023 of EUR 134 million from the cushion focused on country level actions to complement ongoing efforts to facilitate production and access to vaccines in Africa through MAV+. This second special measure of EUR 266 million from the cushion will further reinforce and complement the implementation of MAV+ by concentrating its efforts on the demand for vaccines produced in Africa, interventions aimed at the strengthening of the health system to ensure delivery and equitable access for the population at country

---

<sup>1</sup> OJ L 193, 30.7.2018, p.1.

<sup>2</sup> OJ L 209, 14.6.2021, p.1.

<sup>3</sup> [www.sanctionsmap.eu](http://www.sanctionsmap.eu). Note that the sanctions map is an IT tool for identifying the sanctions regimes. The source of the sanctions stems from legal acts published in the Official Journal (OJ). In case of discrepancy, the OJ prevails.

level in African countries and deploying digital tools for quality assurance for vaccines and other health products

- (4) The action entitled “second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024” will contribute to increase the availability of and access to quality assured vaccines and other essential health products and technologies in Africa through 3 interventions tackling different critical bottlenecks of global and national pharmaceutical supply chains. (i) The contribution to the African Vaccine Manufacturing Accelerator (AVMA) will address the critical issue of demand side barriers to manufacturing and access to health products and technologies in Africa. (ii) The contribution to Gavi 6.0 program for 2026-2030 focusing on health systems strengthening in beneficiary countries in Sub-Saharan Africa to, in particular, strengthen the elements of their health systems which are most critical to the delivery of immunisation services and will increase equitable and sustainable use of vaccines at country level. (iii) The rollout and upscale of the traceability and verification system (TRVST) aims to ensure the quality of health products through digital tools for the detection of counterfeit and falsified health products.
- (5) The objective and design of the action “Second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024”, fulfil the criteria for Official Development Assistance established by the OECD/DAC, as per the requirements of Article 3(3) of Regulation (EU) 2021/947, contributing to the sustainable development of partner countries and the implementation of the 2030 agenda. The countries benefiting from the action which are included in the list of ODA recipients, are identified in the respective action document.
- (6) It is appropriate to authorise the award of grants without a call for proposals and to provide for the conditions for awarding those grants.
- (7) Pursuant to Article 26(1) of Regulation (EU) 2021/947 indirect management is to be used for the implementation of the action.
- (8) The Commission is to ensure a level of protection of the financial interests of the Union with regards to entities and persons entrusted with the implementation of Union funds by indirect management as provided for in Article 157(3) of the Financial Regulation.
- (9) To this end, such entities and persons are to be subject to an assessment of their systems and procedures in accordance with Article 157(4) of the Financial Regulation<sup>4</sup> and, if necessary, to appropriate supervisory measures in accordance with Article 157(5) thereof before a contribution agreement can be signed.
- (10) It is necessary to allow for the payment of interest due for late payment on the basis of Article 116(5) of the Financial Regulation.
- (11) In order to allow for flexibility in the implementation of the measure, it is appropriate to determine the changes which should not be considered substantial for the purposes of Article 110(5) of the Financial Regulation.

---

<sup>4</sup> Except for the cases referred to in Article 157(7) of the Financial Regulation, where the Commission may decide, not to require an ex-ante assessment.

- (12) The measure provided for in this Decision is in accordance with the opinion of the NDICI Global Europe Committee established under Article 45 of Regulation (EU) 2021/947.

HAS DECIDED AS FOLLOWS:

*Article 1*  
*The measure*

The annual financing decision, constituting the annual measure for the implementation of the second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024, as set out in the Annex, is adopted.

The measure shall include the following action “Second special measure to enhance manufacturing capacities and access to vaccines, medicines and health technologies and systems in Africa for 2024” set out in the Annex.

*Article 2*  
*Union contribution*

The maximum Union contribution for the implementation of the measure for 2024 is set at EUR 266 000 000, and shall be financed from the appropriations entered in the following lines of the general budget of the Union :

- (a) budget line 14.020120-C1-INTPA West Africa;
- (b) budget line 14.020121-C1-INTPA East and Central Africa;
- (c) budget line 14.020122-C1-INTPA Southern Africa and Indian Ocean.

The appropriations provided for in the first paragraph may also cover interest due for late payment.

*Article 3*  
*Methods of implementation and entrusted entities or persons*

The implementation of the actions carried out by way of indirect management, as set out in the Annex, may be entrusted to the entities or persons referred to or selected in accordance with the criteria laid down in point 4.4.4 of the Annex.

*Article 4*  
*Flexibility clause*

Increases or decreases of up to EUR 10 000 000 and not exceeding 20% of the maximum Union contribution set in the first paragraph of Article 2, or cumulated changes<sup>5</sup> to the allocations of specific actions not exceeding 20% of that contribution, as well as extensions of the implementation period shall not be considered substantial for the purposes of Article 110(5) of the Financial Regulation, where these changes do not significantly affect the nature and objectives of the actions.

---

<sup>5</sup> These changes can come from assigned revenue made available after the adoption of the financing decision.

The authorising officer responsible may apply the changes referred to in the first paragraph. Those changes shall be applied in accordance with the principles of sound financial management and proportionality.

*Article 5*  
*Grants*

Grants may be awarded without a call for proposals in accordance with the conditions set out in the Annex. Grants may be awarded to the bodies selected in accordance with point 4.4.1 of the Annex.

Done at Brussels, 18.12.2024

*For the Commission*  
*Jozef SÍKELA*  
*Member of the Commission*